BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 19349572)

  • 1. Use of pharmacologic agents for treatment of diabetes mellitus, dyslipidemia, and hypertension in children and adolescents.
    Daniels SR
    Arch Pediatr Adolesc Med; 2009 Apr; 163(4):389-91. PubMed ID: 19349572
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence of antihypertensive, antidiabetic, and dyslipidemic prescription medication use among children and adolescents.
    Liberman JN; Berger JE; Lewis M
    Arch Pediatr Adolesc Med; 2009 Apr; 163(4):357-64. PubMed ID: 19349565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solvay addresses unmet needs in the management of hypertensive patients with cardiometabolic and lipid disorders.
    Cardiovasc J Afr; 2009; 20(1):73-4. PubMed ID: 19287821
    [No Abstract]   [Full Text] [Related]  

  • 4. Meeting of the minds. Should pre-hypertension in type 2 diabetes be treated?
    Bihl G; Amod A; Ellis G; Moore R; Raal FJ; Gernholtz T; Schamroth C; Horak A
    Cardiovasc J Afr; 2010; 21(3 Suppl):S9-S13. PubMed ID: 20532426
    [No Abstract]   [Full Text] [Related]  

  • 5. Antihypertensive, antidiabetic and lipid-lowering treatment frequencies in France in 2010.
    Tuppin P; Ricci-Renaud P; de Peretti C; Fagot-Campagna A; Gastaldi-Menager C; Danchin N; Alla F; Allemand H
    Arch Cardiovasc Dis; 2013 May; 106(5):274-86. PubMed ID: 23769402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).
    Graham I; Atar D; Borch-Johnsen K; Boysen G; Burell G; Cifkova R; Dallongeville J; De Backer G; Ebrahim S; Gjelsvik B; Herrmann-Lingen C; Hoes A; Humphries S; Knapton M; Perk J; Priori SG; Pyorala K; Reiner Z; Ruilope L; Sans-Menendez S; Op Reimer WS; Weissberg P; Wood D; Yarnell J; Zamorano JL; Walma E; Fitzgerald T; Cooney MT; Dudina A; Vahanian A; Camm J; De Caterina R; Dean V; Dickstein K; Funck-Brentano C; Filippatos G; Hellemans I; Kristensen SD; McGregor K; Sechtem U; Silber S; Tendera M; Widimsky P; Zamorano JL; Altiner A; Bonora E; Durrington PN; Fagard R; Giampaoli S; Hemingway H; Hakansson J; Kjeldsen SE; Larsen ML; Mancia G; Manolis AJ; Orth-Gomer K; Pedersen T; Rayner M; Ryden L; Sammut M; Schneiderman N; Stalenhoef AF; Tokgözoglu L; Wiklund O; Zampelas A; ; ; ; ; ; ; ; ; ;
    Eur J Cardiovasc Prev Rehabil; 2007 Sep; 14 Suppl 2():E1-40. PubMed ID: 17726406
    [No Abstract]   [Full Text] [Related]  

  • 7. Biomarkers, atherosclerosis and cardiovascular events.
    Rosenson RS
    Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):619-22. PubMed ID: 18510479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introductory remarks.
    Velasco M; Bermúdez V; Israili ZH; Hernández-Hernández R
    Am J Ther; 2010; 17(3):236. PubMed ID: 20479578
    [No Abstract]   [Full Text] [Related]  

  • 9. Age- and gender-specific awareness, treatment, and control of cardiovascular risk factors and subclinical vascular lesions in a founder population: the SardiNIA Study.
    Scuteri A; Najjar SS; Orru' M; Albai G; Strait J; Tarasov KV; Piras MG; Cao A; Schlessinger D; Uda M; Lakatta EG
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):532-41. PubMed ID: 19321325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients.
    Mazzaglia G; Ambrosioni E; Alacqua M; Filippi A; Sessa E; Immordino V; Borghi C; Brignoli O; Caputi AP; Cricelli C; Mantovani LG
    Circulation; 2009 Oct; 120(16):1598-605. PubMed ID: 19805653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brief comments on the issue of cardiovascular risk in diabetic patients.
    Lasaridis AN
    Am J Hypertens; 2004 Jul; 17(7):640. PubMed ID: 15233987
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of lipid-lowering drug therapy in children and adolescents.
    Avis HJ; Vissers MN; Wijburg FA; Kastelein JJ; Hutten BA
    Curr Opin Investig Drugs; 2009 Mar; 10(3):224-31. PubMed ID: 19333879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Availability and utilization of cardiovascular fixed-dose combination drugs in the United States.
    Wang B; Choudhry NK; Gagne JJ; Landon J; Kesselheim AS
    Am Heart J; 2015 Mar; 169(3):379-386.e1. PubMed ID: 25728728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current unmet need in type 2 diabetes mellitus: addressing glycemia and cardiovascular disease.
    Levy P
    Postgrad Med; 2009 May; 121(3 Suppl 1):7-12. PubMed ID: 19494472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated control of hypertension, dyslipidemia and carotid atherosclerosis in the reduction of cardiovascular risk.
    Riccioni G
    Expert Rev Cardiovasc Ther; 2007 May; 5(3):371-4. PubMed ID: 17489661
    [No Abstract]   [Full Text] [Related]  

  • 16. [Diabetic nephropathy].
    Morcos M; Zeier M; Schwenger V
    Dtsch Med Wochenschr; 2007 May; 132(19):1039-42. PubMed ID: 17476634
    [No Abstract]   [Full Text] [Related]  

  • 17. Antiplatelet activity of drugs used in hypertension, dyslipidemia and diabetes: Additional benefit in cardiovascular diseases prevention.
    Sepúlveda C; Palomo I; Fuentes E
    Vascul Pharmacol; 2017 Apr; 91():10-17. PubMed ID: 28342822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of dyslipidemia and general ineffectiveness of its treatment in both primary and secondary prevention of coronary heart disease within family medicine framework--results of LIPIDOGRAM 2005--a nationwide epidemiological study. Dyslipidemia in Poland--ineffective treatment.
    Konduracka E; Jóźwiak J; Mastej M; Lukas W; Tykarski A; Szczepaniak-Chicheł L; Piwowarska W
    Przegl Lek; 2008; 65(12):834-7. PubMed ID: 19441674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suboptimal use of cardioprotective drugs in newly treated elderly individuals with type 2 diabetes.
    Sirois C; Moisan J; Poirier P; Grégoire JP
    Diabetes Care; 2007 Jul; 30(7):1880-2. PubMed ID: 17384345
    [No Abstract]   [Full Text] [Related]  

  • 20. Free fatty acid receptor family: novel targets for the treatment of diabetes and dyslipidemia.
    Bernard J
    Curr Opin Investig Drugs; 2008 Oct; 9(10):1078-83. PubMed ID: 18821469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.